tradingkey.logo

Scancell Holdings Reports Strong Phase 2 Data On iSCIB1+ In Melanoma

ReutersJul 22, 2025 6:44 AM

- Scancell Holdings PLC SCLP.L:

  • SCANCELL HOLDINGS PLC: STRONG PHASE 2 DATA ON ISCIB1+ IN MELANOMA

  • SCANCELL HOLDINGS PLC - ISCIB1+ SHOWS 69% RESPONSE RATE, EXCEEDS STANDARD CARE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI